Market Cap : 1.42 B | Enterprise Value : 1.25 B | PE Ratio : 158.39 | PB Ratio : 5.71 |
---|
NAS:CARA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:CARA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cara Therapeutics's enterprise value is $1,246.3 Mil. Cara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was $5.6 Mil. Therefore, Cara Therapeutics's EV-to-EBITDA for today is 222.80.
During the past 10 years, the highest EV-to-EBITDA of Cara Therapeutics was 236.02. The lowest was -180.91. And the median was -6.16.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2021-04-17), Cara Therapeutics's stock price is $28.510000. Cara Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $0.18. Therefore, Cara Therapeutics's PE Ratio for today is 158.39.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.
* The bar in red indicates where Cara Therapeutics's EV-to-EBITDA falls into.
Cara Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 1246.337 | / | 5.594 | |
= | 222.80 |
Cara Therapeutics's current Enterprise Value is $1,246.3 Mil.
Cara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was -29.953 (Mar. 2020 ) + -25.836 (Jun. 2020 ) + -16.969 (Sep. 2020 ) + 78.352 (Dec. 2020 ) = $5.6 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cara Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 28.510000 | / | 0.18 | |
= | 158.39 |
Cara Therapeutics's share price for today is $28.510000.
Cara Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was -0.62 (Mar. 2020 ) + -0.54 (Jun. 2020 ) + -0.35 (Sep. 2020 ) + 1.69 (Dec. 2020 ) = $0.18.
* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
No Headline